Ministry of Health: Four Patients With XBB Cases In Indonesia Have Recovered

ILLUSTRATION BETWEEN

JAKARTA - The Ministry of Health stated that four patients with the XBB variant of the COVID-19 case in Indonesia had recovered. It was noted that until Tuesday, October 25 there were a total of four cases of the XBB variant of COVID-19 in Indonesia.

"All patients have mild symptoms such as cough and runny nose. However, all patients have recovered and they are only self-isolating, not hospitalized", said Ministry of Health spokesman Mohammad Syahril quoted by ANTARA, Wednesday, October 26.

Of the four patients, three of them are located in DKI Jakarta with two local transmission patients and one overseas transmission patient. The rest, in Surabaya with the overseas transmission.

"The two overseas transmission patients have a history from Singapore and the two local transmission patients", he said.

According to Syahril, all patients with the XBB variant have received vaccinations, both two doses, and boosters.

The Ministry of Health, he continued, made anticipatory efforts by tracing and testing close contacts following the findings of the XBB case, and the results were negative.

The Ministry of Health warned that the emergence of a new subvariant of COVID-19 has the potential to encourage a spike in cases. Therefore, the public is advised to continue to prioritize health protocols, such as wearing masks, avoiding crowds, and washing hands with soap, as well as testing if they experience signs and symptoms of COVID-19.

"In theory, if there is a spike in cases it is usually associated with a new subvariance", he said.

Syahril appealed to the public to immediately complete the COVID-19 vaccination (two doses), including booster vaccinations to increase protection against COVID-19.

"This vaccine is part of our efforts to give antibodies to the public or to someone to have the strength and not become more seriously ill", he said.

Syahril emphasized that vaccines circulating in the world, including in Indonesia, are currently still effective against the SARS-CoV-2 virus, including for the new subvariant.

The current condition, said Syahril, cannot be said to be safe from the COVID-19 pandemic. "Because various mutations of new variants still have the potential to continue to occur", he said.